FDA Wants To Be “Model” Agency: Preparing For Clinical Trial Simulations

FDA plans to make greater use of mathematical and statistical models to guide drug development and approval decisions, Center for Drug Evaluation & Research Scientific Advisor Donald Stanski said Oct. 5 at a R&D conference sponsored by Phacilitate in Geneva, Switzerland